Who are Roivant Sciences Ltd.'s main suppliers?

Roivant Sciences Ltd. (ROIV) key suppliers include: ARBUTUS, DATAVANT, BioNTech SE, BioNTech SE, Okeanis Eco Tankers Corp. and 3 more. View the full supplier network at chainsifter.com/chain/ROIV.

Who are Roivant Sciences Ltd.'s major customers?

Roivant Sciences Ltd. (ROIV) key customers include: SUMITOMO-PHARMA-CO-LTD, BioNTech SE, BioNTech SE, Immunovant, Inc., Organon & Co. and 12 more. View the full customer network at chainsifter.com/chain/ROIV.

What sector is Roivant Sciences Ltd. in?

Roivant Sciences Ltd. (ROIV) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Roivant Sciences Ltd. Supplier List (ROIV): 8 Verified Suppliers

8Suppliers

17Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Roivant Sciences Ltd. (ROIV) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

28Total relationships

2Distinct source URLs

6High confidence

0.714Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Roivant Sciences Ltd. Suppliers

Ticker	Name	Confidence	Evidence
ARBUTUS	ARBUTUS	90%	The Company holds an investment in Arbutus in the form of 38,847,462 common shares of Arbutus.
DATAVANT	DATAVANT	85%	As of December 31, 2025 and March 31, 2025, the most significant of these were the Company's investments in Arbutus and Datavant, which are accounted for using the fair value option.
BNTX	BioNTech SE	72%	y need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates following regulatory approval, and we have done so from time to time. We may …
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from BNTX graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from BNTX g…
ECO	Okeanis Eco Tankers Corp.	72%	Reciprocal relationship from ECO graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from ECO graph: e, and industry analysts typically measure shipping freight rates in terms of …
IMVT	Immunovant, Inc.	72%	Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT g…
OGN	Organon & Co.	72%	all, which could negatively affect our capacity for certain strategic transactions or our ability to make other important investments. In addition, high levels of inflation and interest rate fluctuat…
OGN	Organon & Co.	72%	Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: all, which could negatively affect our capacity for certain strategic transactions or our ability to make other import…

Roivant Sciences Ltd. Customers

Ticker	Name	Confidence	Evidence
SUMITOMO-PHARMA-CO-LTD	SUMITOMO-PHARMA-CO-LTD	80%	In April 2024, pursuant to this share repurchase program, we entered into a share repurchase agreement with Sumitomo Pharma Co., Ltd. ("Sumitomo") and repurchased all 71,251,083 common shares held by S
BNTX	BioNTech SE	72%	y need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates following regulatory approval, and we have done so from time to time. We may …
BNTX	BioNTech SE	72%	Reciprocal relationship from BNTX graph: Reciprocal relationship from ROIV graph: y need to obtain licenses from third parties to advance our research or allow commercialization of our product candid…
IMVT	Immunovant, Inc.	72%	Reciprocal relationship from IMVT graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from IMVT graph: data from our clinical trials that we announce or publish from time to time …
OGN	Organon & Co.	72%	Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from OGN graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from OGN grap…
OGN	Organon & Co.	72%	of any renegotiated trade agreements, nor can we determine the impact they may have on our business. Any such changes could have a material adverse effect on our business, financial condition and res…
ARBUTUS-BIOPHARMA-CORP	ARBUTUS-BIOPHARMA-CORP	62%	le patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not…
ARBUTUS-BIOPHARMA-CORPORATION	ARBUTUS-BIOPHARMA-CORPORATION	62%	t income” in the condensed consolidated statements of operations. (G) Contingencies The Company may be, from time to time, a party to various disputes and claims arising from normal business activiti…
CATALYST-PHARMS-INC	CATALYST-PHARMS-INC	62%	business, subject us to regulatory actions and cause patients to lose confidence in us or our product candidates, among other negative consequences. Quality management plays an essential role in the …
COMPANY-TELAVANT-PFIZER-INC	COMPANY-TELAVANT-PFIZER-INC	62%	529,978 $ 4,886,891 The following table summarizes the unrealized positions for the Company’s marketable securities (in thousands): As of December 31, 2025 Amortized Cost Gross Unrealized Gains Gross…
GENEVANT-SCIENCES-LTD	GENEVANT-SCIENCES-LTD	62%	le patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not…
IMMUNOVANT-SCIENCES-GMBH	IMMUNOVANT-SCIENCES-GMBH	62%	ses from third parties to advance our research or allow commercialization of our product candidates following regulatory approval, and we have done so from time to time. We may fail to obtain any of …
MODERNA-THERAPEUTICS-INC	MODERNA-THERAPEUTICS-INC	62%	le patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not…
MONTES-ARCHIMEDES-ACQUISITION-CORP	MONTES-ARCHIMEDES-ACQUISITION-CORP	62%	t income” in the condensed consolidated statements of operations. (G) Contingencies The Company may be, from time to time, a party to various disputes and claims arising from normal business activiti…
MRNA	Moderna, Inc.	62%	Reciprocal relationship from MRNA graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from MRNA g…
PFE	Pfizer Inc.	62%	Reciprocal relationship from PFE graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from PFE graph: Reciprocal relationship from ROIV graph: Reciprocal relationship from PFE grap…
ROCHE-HOLDINGS-INC	ROCHE-HOLDINGS-INC	62%	529,978 $ 4,886,891 The following table summarizes the unrealized positions for the Company’s marketable securities (in thousands): As of December 31, 2025 Amortized Cost Gross Unrealized Gains Gross…

Roivant Sciences Ltd. Debt Obligations

Instrument	Description	Confidence	Evidence
ROIV-DEBT-12255	Warrants outstanding: 0.01	90%	xbrl warrant detail from xbrl 2025-03-31.
ROIV-DEBT	Debt stack $222.0M	90%	Market cache reports total debt of $222.0M.

Roivant Sciences Ltd. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Roivant Sciences Ltd..

Roivant Sciences Ltd. Ownership

Holder	Name	Confidence	Evidence
ROIV-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 443 tracked holders.

Roivant Sciences Ltd. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
MRNA	Moderna, Inc.	100.00	1	['customer']
MGNX	MacroGenics, Inc.	100.00	2
IMVT	Immunovant, Inc.	100.00	1	['customer', 'supplier']
BCAX	Bicara Therapeutics Inc.	100.00	2
MC	Moelis & Company	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
OGN	Organon & Co.	100.00	1	['customer', 'supplier']
BPAQF	BP p.l.c.	100.00	2
PFE	Pfizer Inc.	100.00	1	['customer']
AUTL	Autolus Therapeutics plc	100.00	2
COP	ConocoPhillips	100.00	2
ORANY	ORANGE	50.00	2
CMRE	Costamare Inc.	50.00	2
RLAY	Relay Therapeutics, Inc.	50.00	2
ARVN	Arvinas, Inc.	50.00	2
CAH	Cardinal Health, Inc.	50.00	2
IMTX	Immatics N.V.	50.00	2
ESPR	Esperion Therapeutics, Inc.	50.00	2
CELG-RI	BRISTOL MYERS SQUIBB CO	50.00	2
HBIO	Harvard Bioscience, Inc.	50.00	2

Roivant Sciences Ltd. Supply Chain